{"id":69382,"date":"2022-03-25T12:23:21","date_gmt":"2022-03-25T16:23:21","guid":{"rendered":"https:\/\/seniordesign.digitalscholar.rochester.edu\/spring2022\/?p=288"},"modified":"2022-09-12T10:29:31","modified_gmt":"2022-09-12T14:29:31","slug":"anesthesia","status":"publish","type":"post","link":"https:\/\/www.hajim.rochester.edu\/senior-design-day\/anesthesia\/","title":{"rendered":"DetectIV"},"content":{"rendered":"\n

Meet the Team<\/h2>\n\n\n\n
\n
\"\"
Sophie Mackenzie, CEO<\/figcaption><\/figure>\n\n\n\n
\"\"
Theo Couderc, COO<\/figcaption><\/figure>\n\n\n\n
\"\"
Rebecca Mathurin, CTO<\/figcaption><\/figure>\n<\/figure>\n\n\n\n

BioDesign Statement<\/h2>\n\n\n\n

A device for anesthesiologists to detect unwanted infiltration and extravasation from delivery of intravenous fluids to reduce incidence of effects such as pain, swelling and risk of necrosis during the intraoperative period.<\/p>\n\n\n\n

Summary <\/h2>\n\n\n\n

\u201cImprove response times for infiltration and enhance workflow efficiency using DetectIV for continuous monitoring of IVs in real time\u201d<\/em><\/p>\n\n\n\n

DetectIV is a wearable, continuous monitoring medical device that aids anesthesiologists in the detection of infiltration\/extravasation from delivery of intravenous fluids prompting early intervention. >200,000 hospital operating rooms and 35 million annual in-patient stays in the United States use IV therapy. Infrequent visual evaluation remains the current gold standard for monitoring IV sites. 50% of peripheral IVs failing results in adverse effects such as pain, swelling and tissue necrosis when left unattended. <\/p>\n\n\n\n

Background<\/h2>\n\n\n\n
\"\"
IV infiltration statistics [1].<\/figcaption><\/figure><\/div>\n\n\n\n